DNA Methylation in Bladder Cancer: Diagnostic and Therapeutic Perspectives—A Narrative Review
International Journal of Molecular Sciences · 03.08.2025 · 26 (15) · 7507
DOI: 10.3390/ijms26157507 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.08.2025. Verfasst von Dragoş Puia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery II, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: DNA Methylation, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bladder cancer pathogenesis is closely linked to epigenetic alterations, particularly DNA methylation and demethylation processes. Environmental carcinogens and persistent inflammatory stimuli—such as recurrent urinary tract infections—can induce aberrant DNA methylation, altering gene expression profiles and contributing to malignant transformation. This review synthesizes current evidence on the role of DNA methyltransferases (DNMT1, DNMT3a, DNMT3b) and the hypermethylation of key tumour suppressor genes, including A2BP1, NPTX2, SOX11, PENK, NKX6-2, DBC1, MYO3A, and CA10, in bladder cancer. It also evaluates the therapeutic application of DNA-demethylating agents such as 5-azacytidine and highlights the impact of chronic inflammation on epigenetic regulation. Promoter hypermethylation of tumour suppressor genes leads to transcriptional silencing and unchecked cell proliferation. Urine-based DNA methylation assays provide a sensitive and specific method for non-invasive early detection, with single-target approaches offering high diagnostic precision. Animal models are increasingly employed to validate these findings, allowing the study of methylation dynamics and gene–environment interactions in vivo. DNA methylation represents a key epigenetic mechanism in bladder cancer, with significant diagnostic, prognostic, and therapeutic implications. Integration of human and experimental data supports the use of methylation-based biomarkers for early detection and targeted treatment, paving the way for personalized approaches in bladder cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery II, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
- Department of Urology, "Dr. C.I. Parhon" Clinical Hospital, 700503 Iasi, Romania.
- Center for Morphological and Spectroscopic Analysis of Urinary Stones" Michel Daudon", 700503 Iasi, Romania.
ORCID-Profile: Dragoş Puia, Marius Ivănuță
Zitieren
APA
Puia, D., Ivănuță, M., & Pricop, C. (2025). DNA Methylation in Bladder Cancer: Diagnostic and Therapeutic Perspectives—A Narrative Review. International Journal of Molecular Sciences, 26(15), 7507. https://doi.org/10.3390/ijms26157507
Vancouver
Puia D, Ivănuță M, Pricop C. DNA Methylation in Bladder Cancer: Diagnostic and Therapeutic Perspectives—A Narrative Review. International Journal of Molecular Sciences. 2025;26(15):7507. doi:10.3390/ijms26157507
BibTeX
@article{Puia2025,
author = {Puia, Dragoş and Ivănuță, Marius and Pricop, Cătălin},
title = {DNA Methylation in Bladder Cancer: Diagnostic and Therapeutic Perspectives—A Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {15},
pages = {7507},
doi = {10.3390/ijms26157507}
}
EUVIMED